Ausdal Financial Partners Inc. Makes New $1 Million Investment in Pfizer Inc. $PFE

Key Points

• Ausdal Financial Partners initiated a roughly $1.004 million position in Pfizer, purchasing 41,679 shares during the second quarter. Institutional investors collectively own 68.36% of Pfizer’s stock.
• Pfizer exceeded quarterly expectations with adjusted EPS of $0.77 versus a $0.68 estimate and revenue of $15.03 billion, up 2.6% year over year. The company also declared a $0.43 quarterly dividend, representing a 6.1% annualized yield.
• Wall Street’s consensus rating remains Hold, with a $28.28 average price target. Investors are watching Pfizer’s pipeline—including its Lyme disease vaccine review—to offset expected pressure from patent expirations and declining legacy-product sales.

Ausdal Financial Partners Inc. bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 41,679 shares of the biopharmaceutical company's stock, valued at approximately $1,004,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC raised its holdings in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. United Bank grew its holdings in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock worth $1,408,000 after acquiring an additional 6,415 shares during the last quarter. Sei Investments Co. increased its position in Pfizer by 31.5% in the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company's stock valued at $63,889,000 after acquiring an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC increased its position in Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company's stock valued at $2,480,000 after acquiring an additional 31,896 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer has started a European Medicines Agency review for its Lyme disease vaccine. The review is an important regulatory step that could expand Pfizer’s longer-term vaccine portfolio, although it does not guarantee approval or near-term revenue. Pfizer Starts EMA Review For Its Lyme Disease Vaccine
• Positive Sentiment: Recent comparisons with Bristol Myers Squibb suggest Pfizer’s valuation, diversification and oncology portfolio may offer an attractive risk-reward profile. This supports the view that the stock could benefit if new medicines successfully offset declining legacy-product sales. PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
• Positive Sentiment: Analysts are focused on Pfizer’s post-second-quarter pipeline and whether upcoming medicines can reset the company’s growth trajectory. The opportunity is meaningful because Pfizer recently exceeded quarterly earnings and revenue expectations, but execution remains key. How Is Pfizer Shaping Its S&P 500 Pipeline After Q2?
• Neutral Sentiment: Pfizer’s dividend remains appealing to income-oriented investors, but comparisons with Abbott Laboratories emphasize that Pfizer offers more turnaround potential while Abbott has a steadier dividend-growth record and broader diversification. Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
• Neutral Sentiment: Brokerages collectively rate Pfizer “Hold,” indicating that analysts see potential value but lack a strong consensus catalyst for a decisive re-rating. Pfizer Receives Consensus Recommendation of Hold
• Negative Sentiment: Investor caution persists over Pfizer’s need to restore growth before major patent expirations arrive. Articles discussing new medicines frame the pipeline as necessary to counterbalance expected pressure on established products, limiting enthusiasm until launches and approvals produce measurable results. Can New Medicines Reset the Growth Story?

Pfizer Price Performance

Shares of PFE opened at $28.33 on Thursday. The firm has a market cap of $161.47 billion, a PE ratio of 37.28 and a beta of 0.34. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $28.75. The business's 50 day moving average price is $25.44 and its two-hundred day moving average price is $26.29. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer's dividend payout ratio is 226.32%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PFE. Cantor Fitzgerald reiterated a "neutral" rating and set a $27.00 price target on shares of Pfizer in a report on Monday, July 6th. UBS Group reaffirmed a "neutral" rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. Citigroup lifted their target price on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 29th. Guggenheim reduced their price target on Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a research report on Friday, August 7th. Finally, Royal Bank Of Canada raised Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price target for the company in a research note on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $28.28.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source